Summary A number of genetic syndromes are known to convey a high risk of colorectal cancer. Current standards of medical practice for these patients involve genetic testing followed by screening and surgical procedures. Pharmaceutical therapies for any of these syndromes are limited in number and are generally not approved by any regulatory body for applications in these genetic groups. This review discusses advances in mechanistic understanding of the disease processes leading to the development of promising pharmaceutical therapies. Clinical trials of potential chemotherapeutic agents must focus on the reduction of disease-related events, including cancer and cancer-related mortality, in patients with genetic syndromes.
review Laukaitis, Erdman & Gerner cancer (CRC) might be appropriate candidates for chemoprevention, and discussed the importance of prostaglandin metabolism in cancer development and as a potential target for chemopreventive agents [3] . Agents that target COX, especially COX-2, involved in prostaglandin synthesis have been shown to reduce colorectal adenomas (CRAs), which are precursors of CRC, in patients with prior sporadic (nongenetic) CRAs [4] [5] [6] . In spite of these positive findings, the use of COX-2-selective agents to manage patients with average risk of CRC is discouraged [7] . Intake of aspirin, which also inhibits COX activities, has been associated with a reduced risk of CRA in prospective clinical trials [8, 9] and CRC in population studies [10] . In spite of this benefit, concerns over toxicities have prevented clinicians from broadly prescribing aspirin to manage CRC risk, although some authors have suggested application in patients with a higher-than-average risk of CRC [11] . While the syndromes targeted for chemoprevention carry high cancer risks, the patients receiving chemopreventive medications are currently healthy, limiting tolerance for toxicity [12] . Because of this, and because of difficulty in determining what are clinically meaningful end points for studies, no current agent has regulatory approval by either the US FDA or EMA for use in the usual management of patients with either genetic or sporadic risk of CRC (Table 1) . This challenge may be overcome through the use of combinations of agents [13, 14] and, perhaps, in 'personalizing' chemoprevention strategies based on individual patient's pharmacogenomic characteristics.
Familial adenomatosis polyposis
Familial adenomatosis polyposis (FAP) is caused by mutations in the APC gene (the rodent gene is known as Apc). FAP affects approximately three in 100,000 people [15] [16] [17] . People with FAP develop CRC at an average age of 39 years [18] , although there is variability within and between families, some of which correlates with the specific causative mutation [19] . FAP patients are also at risk for extracolonic manifestations including gastric and duodenual polyps, osteomas and dental anomalies, congenital hypertrophy of the retinal pigment epithelium, desmoids and other soft tissue tumors. The current standard of treatment includes intensive monitoring with prophylactic surgery (either restorative proctocolectomy or ileorectal anastomosis [IRA] ) when the adenoma burden becomes unmanageable by endoscopy, often by 20 years of age [20, 21] . While surgery is life-saving [22] , reported postoperative quality-of-life outcomes are highly variable [23] [24] [25] [26] and suggest that surgery may increase the risk of infertility [27, 28] . The very high risk of CRC, and the young age at which FAP patients undergo preventive surgery make chemoprevention attractive. Significant preclinical work has led to the development of agents whose efficacy has been tested in clinical trials (Table 2) .
Clinical trials of chemopreventive agents in FAP used CRA and/or duodenal polyp number or burden as primary end points. The clinical significance of these end points is questionable, given the current standard of care by screening and surgical treatment with colectomy or proctocolectomy. The current most clinically 
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relevant disease sites in FAP are the rectum, ileal pouch, duodenum and abdominal desmoids [29] . End points with clinical meaning relevant to pharma cologic adjunct to standard of care include increasing the time to FAP-related events that influence morbidity and mortality from this genetic disease. Current medical practice utilizes diagnostic and surgical methods to monitor and treat FAP patients. While surgical procedures can effectively eliminate the risk of colorectal cancer, patients must deal with subsequent sequelae involving surgical repairs, duodenal polyposis, development of desmoid tumors in a subset of patients and subsequent cancers le ading to death. Chemoprevention may have the consequence of reducing disease incidence or onset or suppressing the course and/or severity of disease and/or disease-related sequelae. Chemoprevention would not have to prevent cancer; even postponing uncontrollable polyp development by 5-10 years would delay surgery long enough for patients to develop a stable identity and to reproduce [30] .
For chemoprevention strategies to be implemented in clinical practice, strategies must address current unmet medical needs and/or improve the patient's quality of life. Table 1 lists a number of past and current efforts to develop pharmaceutical agents for use in the management of patients with FAP, many of which target the prostaglandin-COX pathway.
Nonselective inhibition of prostaglandin synthesis
NSAIDs including aspirin, sulindac and indomethacin, inhibit COX-1 and COX-2 and signaling through WNT and other pathways, and have been studied extensively in chemoprevention of CRAs and in FAP [31] . The CAPP1 trial examined whether aspirin (600 mg/day) and/or resistant starch (RS; 30 g/day) reduced polyp number in the rectum and sigmoid colon of young patients with FAP [32] . The largest polyp size in each individual was a secondary end point. This study relied on participants having intact colons, so patients aged 10-21 years were recruited. The average age of enrollment was 18 years and approximately half of the participants were female. The median time to endoscopic polyp assessment was 17 months, so more than half of patients remained on treatment for over a year. A total of 206 patients were randomized to receive RS alone, RS plus aspirin, aspirin alone or placebo, and 133 underwent follow-up endoscopy. Neither aspirin nor RS significantly reduced polyp number or size, although there was a trend towards fewer polyps and smaller largest polyp size in the patients treated with aspirin. Secondary analyses found a significant reduction in polyp size for patients who received aspirin and remained on the study for more than a year. RS had no effect. This is similar to CAPP2 findings with aspirin in Lynch syndrome [33] . An ongoing trial is studying whether aspirin and difluoromethylornithine (DFMO) are s ynergistic [101] .
Giardiello and colleagues studied the nonselective COX inhibitor sulindac (150 mg twice daily) in patients with polyposis, most of whom had intact colons [34] . At 9 months, there was a significant reduction in polyp number and size, although these increased after stopping the medication. A 48-month trial in FAP patients without polyposis found no reduction in number or size of polyps [35] . Postsurgical patients treated with sulindac at 300-400 mg daily showed significant reduction in rectal polyp number and size [36, 37] . The second showed a nonsignificant improvement in duodenal polyps [37] . These are similar to eight nonrandomized trials showing reduction in polyp load (reviewed in [38] ). Several current trials are studying sulindac in FAP patients [39] , including one in conjunction with probiotics
The NSAID indomethacin has been studied in short-term (1-11 months) nonrandomized trials for patients with previous IRA, with rectal polyp number as the end point [40, 41] . Polyp numbers decreased after indomethacin given either by suppository or orally, and reached statistical significance in the oral trial.
Exisulind (sulindac sulfone) has limited activity against COX enzymes, but retains WNT inhibition. Efficacy in stopping polyp formation or causing polyp regression has been reported in one randomized, double-blind placebo-controlled trial and two nonrandomized trials [42] [43] [44] . Preliminary work showed that treatment with exisulind 600 mg daily for 6-24 months caused significant polyp regression (>50%) and inhibition of new polyp formation (25-50%) [43, 44] . The randomized trial studied exisulind at a dose of 100 or 200 mg twice daily (200-400 mg total) in 155 patients with FAP and adenomatous polyps. In the higher-dose group, they reported a similar reduction in polyp size (50%; p = 0.03 in the efficacy evaluable population, but not significant for the intention-to-treat group) as well [42] . The occurrence of all of these effects was significantly higher in the 400-mg arm than the placebo or 200-mg cohorts and 38% of people in the exisulind 400-mg group discontinued the study prematurely [42] . A clinical trial to study the efficacy of exisulind in preventing polyp formation in FAP patients was withdrawn [103] .
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Selective inhibition of COX-2
Agents targeting COX-2 have been a major focus of attention, in part due to preclinical studies in mouse models of FAP that identified COX-2 as a mediator of tumorigenesis resulting from loss of function of the APC tumor-suppressor gene. In addition to their inhibition of COX activity, these agents inhibit b-catenin activity. Celecoxib (Celebrex ® , Pfizer, KS, USA) has been evaluated alone and in combination with other agents. Celecoxib was approved over 10 years ago by both the US FDA and by the EMA for use in the treatment of FAP, based on statistically significant 28% reductions in total colorectal polyps and 30% reduction in polyp burden [45] . Furthermore, management of FAP evolved in such a way that most FAP patients received colectomy/proctocolectomy, and thus colorectal adenomas were not a significant clinical problem in most patients. These clinically significant issues, along with agent toxicity limiting recruitment to a postmarketing registry, resulted in withdrawal of regulatory approval for the FAP indication for celecoxib in 2011. Current clinical trials are evaluating the potential of celecoxib alone in pediatric FAP patients or in combination with other agents (Table 2) .
Other COX-2 inhibitors have been studied in randomized and nonrandomized trials. Rofecoxib at 25 mg daily was studied in patients with previous IRA for 9-30 months. It caused a significant decrease in both polyp number and size [46, 47] . Surprisingly, a randomized trial of tiracoxib at 150-200 mg daily for 6 months failed to show a change in polyp size or number [48] . Neither is available commercially.
COX-2-selective inhibitors as primary colorectal cancer prevention have fallen out of favor due to unexpected cardiovascular events [4, [49] [50] [51] and a recent pooled ana lysis of cardiovascular events in six clinical trials of nonarthritis patients demonstrates that celecoxib is indeed associated with a dose-dependent increased risk of cardiovascular events [52] .
Polyamine inhibition
Preclinical studies have identified the rationale for combinations of sulindac with other agents, including inhibitors of EGF signaling pathways [53] and polyamine metabolism [32] . These studies have also identified downstream genes regulated by the APC tumor-suppressor gene using genetically modified human colon tumor-derived cells. The MYC oncogene is one of these APC-regulated genes [54] . MYC regulates a number of genes and pathways, including the polyamine pathway [55] . Agents that suppress intestinal and colonic polyamine contents, including the ornithine decarboxylase inhibitor DFMO and several NSAIDs, inhibit intestinal and colonic tumorigenesis in the Apc
Min/+ mouse model of FAP [55, 56] . Results from these preclinical human cell and rodent models were subsequently translated into a series of Phase II/III studies in patients with prior sporadic colorectal polyps. After dosefinding, safety and biochemical efficacy studies were completed. The combination of DFMO and sulindac reduced total and advance/multiple metachronous colorectal adenomas by 70% and greater than 90%, respectively, in patients with prior sporadic colorectal polyps [53] . These preclinical and clinical studies are the rationale for a new clinical trial to study the efficacy of DFMO and sulindac, alone or in combination, in adult FAP patients [104] .
CPP-FAP-310 is a trial planned to study the efficacy of DFMO and sulindac in adult FAP patients [104] . It is unique in that the outcomes studied will be timed to a FAP-related event (polypectomy, surgery or bleeding) (Table 2 ). This new trial will focus on clinically significant events involving intestinal polyposis. Major eligibility criteria for this trial will include diagnosis of genotypic and/or phenotypic FAP or attenuated FAP (AFAP), and an age of 18 years or over; and in the case of prior colorectal surgery, at least 3 years since colectomy/proctocolectomy with IRA or pouch. Patients will be randomized to one of three arms, as shown in the schema presented in Figure 1 . The trial is designed to measure the time to clinically significant events and is based on an estimated total event number. The treatment period is expected to last 2 years.
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Other agents
Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid that is found naturally in cold-water fish and has been suggested to have protective effects against CRC. Its mechanism is not clear, but EPA may act through inhibition of COX-2 enzyme activity and WNT signaling [57] . Using a protocol similar to that used for celecoxib [45] , West and colleagues conducted a double-blind, randomized, placebo-controlled trial to ask whether EPA reduced polyp load in the rectum of people with FAP treated with IRA [58, 105] . Participants were over 18 years of age and had undergone a colectomy with IRA for FAP risk reduction at least 1 year prior to enrollment. A total of 58 participants were randomized to either 2 g daily of an enteric-coated EPA or placebo, and rectal endoscopy was performed to assess rectal polyp burden after 6 months of medication. Individuals taking EPA had a ~12% reduction in both polyp number and size after 6 months, compared with a 10% (number) and 30% (size) increase in people from the placebo arm. The differences in polyp number, change in polyp number and change in polyp diameter were statistically significant between treatment and placebo groups, as was the 42% reduction in global rectal polyp burden between the groups (p = 0.011). The direction and magnitude of polyp reduction is similar between EPA and celecoxib [58] . It is hoped that the improved side-effect profile of EPA (e.g., fish oil) compared with celecoxib, with its increased cardiovascular risk, will make this a more attractive c hemopreventive agent.
Treatment of 19 FAP patients with 3 g of vitamin C daily for 9 months showed a significant reduction in polyp area compared with 17 controls, although polyp number was never significantly reduced. A later trial combining vitamins C and E, with or without grain fiber, showed a trend toward reduction in polyp number by fiber, but not by vitamin treatment [59] . Treating 25 post-IRA FAP patients with oral calcium carbonate 1500 mg for 6 months showed no difference in polyp number or size, although there were lower crypt cell production rates in rectal biopsies from treated patients [60] . Curcumin and quercetin reduced polyp number and size in four patients with previous surgery [61] . Other trials of natural agents, including black raspberry extract and probiotics, have yet to be reported or completed.
Lynch syndrome
Hereditary nonpolyposis colorectal cancer (HNPCC) kindreds were initially identified by use of the Amsterdam Criteria based on familial and clinical features [62] . A later revised criteria included extraintestinal cancers as well as tumor histology (Bethesda Criteria) [63, 64] . Approximately half of these families have a disease-causing mutation in one of four DNA mismatch repair (MMR) genes MSH2, MLH1, MSH6 and PMS2, providing a genetic explanation and allowing this latter group to be further defined as Lynch syndrome (LS), an autosomal dominant disorder of variable penetrance. Individuals with LS have up to an 80% lifetime risk of developing CRC as well as extraintestinal cancers, including endometrial, ovarian, urinary, brain and others. Inactivation of the MMR genes can occur in sporadic CRC where gene silencing takes place due to hypermethylation of the promoter region [65] . Somatic loss of the second MMR allele inactivates the mismatch repair system, leading to genome-wide mutagenesis resulting in the early development of colon adenomas that rapidly progress through the adenoma-carcinoma sequence. As the most common inherited colorectal cancer syndrome in western countries, 
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LS accounts for 3-5% of all CRCs with MMR gene mutation carrier rate of approximately one in 3000 [66] . Simultaneous cancers (synchronous malignancy) as well as recurrent or later cancers in both colon and other organs (metachronous malignancy) are a hallmark of LS. This is the basis for aggressive therapeutic and prophylactic surgical management in the setting of CRC in LS patients [67, 68] . Published surveillance guidelines have been shown to improve survival in patients with LS [69] ; however, there is continued interest in methods to reduce cancer risk. Chemoprevention may prove effective both clinically and from a cost perspective, although it is not as well studied in LS as in FAP. As a heterogeneous disease, no single common mechanism or pattern of gene mutations are common to all sporadic or LS CRCs. Genes such as COX-2 are more commonly involved with elevated mRNA and protein levels in up to 50% of adenomas and 80% of sporadic CRCs. In studies comparing COX-2 overexpression with MMR status, COX-2 overexpression was observed in 79% of tumors with intact MMR repair compared with 48% with deficient; MMR system (p < 0.001). COX-2 overexpression decreases in the setting of defective MMR [70, 71] . Nonetheless, chemopreventive agents targeting COX overexpression have received the greatest attention although these drugs are also likely to have other COXindependent mechanisms [72] . Here, we review the preclinical studies since they highlight agents that may be promising for future study, as well as the few reported clinical trials.
Rodent models
Mouse models carrying germline mutations of the homologous MMR genes have been present for over two decades. Unlike human disease, mice with heterogeneous mutation in the MMR genes do not display tumor development, rendering these models of limited value in chemo prevention studies. This lack of tumor development is thought to be secondary to the shorter lifespan of mice, significantly limiting the time available to silence the normal wild-type (WT) allele and fewer cell numbers due to body size. Mice possessing germline mutation of both alleles display a cancer phenotype differing from that of LS with lymphoma and skin tumors along with GI tract tumors that are predominantly small intestinal. This phenotype is nearly identical to that seen in children and adolescents that carry biallelic germline mutations of the MMR genes [73, 74] .
Utilizing a Cre-LoxP-mediated inactivation of Msh2, a conditional Msh2-knockout mouse model has been created (VC-Msh2-/LoxP) that develops intestinal adenomas and adenocarcinomas without the lymphomas or skin tumors noted in other animal models [75] . This model more closely approximates LS colon cancer and would appear to be an ideal model for the testing of chemopreventive agents. This model was recently used to assess the effect of aspirin and low-dose nitric oxide donating aspirin (NO-ASA) [76] . Treatment with either drug at lower doses increased lifespan by 18-21% when compared with controls; however, drug treatment had minimal effect on eventual tumor numbers, with aspirin treatment tending to reduce microsatellite instability, which was not seen in the NO-ASA treatment group. By contrast, highdose NO-ASA treatment increased microsatellite instability and tumor burden with a decreased lifespan [77] .
The nonselective NSAID sulindac was studied in a Mlh1
+/-mouse model as part of a group study including an Apc 1638N/+ mouse model with contrasting results. After 6 months of treatment by addition to the diet, small intestinal tumor number and mucosal inflammation was decreased, as expected, in the Apc model but small intestinal inflammation and tumor numbers were increased in the Mlh1 +/-animals. Sulindac treatment increased cecal tumor number and inflammation in all animals regardless of genetic background, suggesting a connection between inflammation and tumor formation [78] . Another study in a mouse model with both Apc and Msh2 mutations (Apc min/-Msh2 -/-) found that the specific COX-2 inhibitor MF-tricyclic had a greater effect on suppressing small bowel tumors than sulindac when compared with controls. Neither treatment affected tumor number or aberrant crypt foci in the colon [79] . The effects of sulindac on tumor prevention in Msh2 and p53 mouse models with a WT control using azozymethane to drive tumor formation has also been reported. Sulindac blocked azozymethaneassociated tumor formation in the distal colon of all animals. Sulindac treatment was associated with proximal colonic inflammation that progressed to adenocarcinoma in up to 25% of either the p53-or Msh2-deficient mice but not in the WT controls [80] . Collectively, these three animal studies show that sulindac can influence tumor development in genetically predisposed mouse models on a regional basis. However, they
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also argue for regional drug-associated changes in mucosal inflammation that appear to be associated with increased tumor formation suggesting a secondary, dose-dependent proinflammatory effect that may also play a role in carcinogenesis.
Human studies Aspirin
The largest clinical trial of LS to date (the CAPP2 trial) was a randomized placebo-controlled trial using a 2 × 2 factorial design in genotype-positive patients (n = 746 included in final ana lysis) that received either aspirin at a dose of 600 mg per day, resistant starch (Novelose ® , National Starch Food Innovation, NJ, USA) at a dose of 30 g per day, both or placebo for up to 4 years. Initial data ana lysis at 2.5 years of follow-up showed no statistical significant reduction for adenoma incidence with either treatment separately or combined (relative risk [RR]: 1.03; 95% CI: 0.75-1.41) or colorectal cancer incidence (RR: 0.87; 95% CI: 0.39-1.96) [81] . However, additional follow-up at four years found a significant reduction in time to first colon and other LS cancers between aspirin and placebo groups (HR: 0.62; 95% CI: 0.41-0.96) [32] . This suppressive effect of aspirin was seen long after the medication was discontinued, arguing for a delayed chemo preventive effect. A similar therapeutic deferral has been documented in observational studies of regular aspirin users where a reduction in cancer was seen after 10 years [82, 83] . Due to the rapid progression from adenoma to carcinoma known to occur in LS, a significant number of the cancers identified at follow-up surveillance developed after discontinuation of treatment. The authors comment on a possible mechanism of enhanced apoptosis possibly affecting aberrant stem cells that are destined to progress quickly to cancer. Cell culture work in MMR-deficient cells treated with aspirin show increased apoptosis and reduced microsatellite instability [77] .
Sulindac
The nonselective COX inhibitor sulindac has been studied in an HNPCC patient population (defined MMR family mutation with a previously diagnosed HNPCC-related cancer or polyp) to assess the effect of treatment on proliferation and apoptosis, as assessed in colon biopsies on and off treatment. Using a randomized, double-blinded, placebo-controlled cross-over study design, 22 subjects were treated with sulindac 150 mg twice daily or 4 weeks of placebo separated by a 4-week washout period. This short duration study found increased markers of proliferation in the right colon, but not in the left, when comparing treatment with placebo. No change was noted in markers of apoptosis (staining of cytokeratin 18 cleavage products) or levels of Cyclins B1, D3 and E and p21, p27, BAX and BCL by i mmunohistochemistry [84] .
Other agents
Hormonal agents are being formally studied for prevention of uterine cancer (Table 2) . These agents are attractive in light of the possibility that they might also protect against colorectal cancer [85] .
MUTYH-associated polyposis
In addition to FAP and LS, a third adenomatous polyposis syndrome was identified in 2002 and found to be due to biallelic mutation in the base excision repair gene MUTYH [86] . The three disorders share a similar phenotype of variable colorectal adenomas and increased the risk of CRC; however, MUTYH-associated polyposis (MAP) is inherited as an autosomal recessive disorder with typical onset in the fourth or fifth decade with limited numbers of adenomas prominently in the right colon. Duodenal adenomas and extraintestinal malignancies of the bladder, ovary and skin are part of the MAP phenotype, which again overlaps with both features of attenuated FAP and LS [87] . Chemoprevention in MAP remains to be addressed.
Chemoprevention in the hamartomous polyp syndromes
Several of the less-common polyp syndromes are characterized by development of hamartomatous polyps throughout the GI tract. These are also associated with significant cancer risk and, as such, people with these syndromes could benefit from effective chemo prevention strategies. Most are due to specific gene mutations that affect signaling pathways that regulate cell growth, maturation and adhesion with dysregulation of COX-2 expression a common finding (Table 3) . Neoplasia is thought to develop through either a hamartoma-adenoma-carcinoma sequence or through a 'landscaper mechanism' that postulates that the abnormal stromal environment of the hamartoma enables carcinogenic transformation in the adjacent epithelium [88] . These autosomal dominant syndromes show great variation in expression and convey both gastrointestinal and Table 3 .
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Optimal chemoprevention for these syndromes should be both safe, effective and target other potential cancer sites in a ddition to the colon.
Future perspective
Chemoprevention of cancer in carriers of genetic traits that predispose to cancer is not implemented in the usual clinical management of these patients for several reasons. A major reason has been ineffectiveness of drug therapy. An example of this lack of efficacy is the treatment of FAP with celecoxib, which was referred to earlier. This agent administered as a single agent produced statistically significant, but clinically insignificant, responses [45] . In spite of regulatory body approvals, the agent did not become a standard feature of management of patients with FAP and the sponsor subsequently withdrew the agent from this market. Successful implementation of chemoprevention in the management of these patients will require that agents successfully address unmet clinical needs, be effective in improving clinical outcomes and display safety profiles that do not exceed benefits and are acceptable to patients. For example, toxicities of agents such as tamoxifen remain problematic and negatively impact patient acceptance [12] . Solutions to these dilemmas may be found in the use of combinations of agents [13] , a strategy that has already shown positive results in patients with sporadic risk of CRC [53] . Whether chemoprevention strategies can be prescribed in a 'personalized medicine' manner in the future remains to be determined. Information regarding rare alleles (i.e., <1% in the general population) is already attainable and is beginning to be used in decisions for chemoprevention of genetic risk groups. An example is the use of aspirin in patients with hereditary nonpolyposis colon cancer [33] . Information regarding more common alleles (i.e., >5% in the general population) may also be useful in the future. Studies in sporadic patients indicate that polymorphisms in specific genes may identify the responsiveness of patients to the colorectal adenoma preventive activity of aspirin in patients with sporadic risk of colorectal cancer [89] . Some of these common poly morphisms may be useful in predicting responses to combinations of agents [90] . Measures of certain tissue properties may also be helpful in prediction of agent utility. For example, measures of rectal prostaglandin and polyamine contents appear to be associated with responses in patients with sporadic risk of CRC [91] . Future studies will determine if any of these genetic, biochemical or other types of measures can be used to 'personalize' c hemoprevention for patients with genetic risk of cancer.
There is a significant need for new treatments to complement existing diagnostic and surgical methods for patients with genetic risk of colorectal and other syndrome-associated cancers. Over the next 5 years, studies will evaluate effects of pharmaceutical strategies on unmet medical needs in these patients, in order to assess therapeutic risks and benefits. Agents will be selected for efficacy to convey a specific treatment benefit, but these benefits may not be limited to reducing the risk of CRC death. Other clinically significant end points include reduction in diseaseassociated sequelae (e.g., subsequent surgeries and related treatment complications). Studies focusing more broadly on current unmet medical needs will allow for more rapid determination of clinical benefit of new interventions than those that only consider cancer or mortality end points.
Clinical studies need to address questions of agent dose and duration. Combinations of agents have the potential to reduce individual agent dose prescriptions as a way of reducing treatment toxicities. Investigators need to determine if pharmaceutical therapies need to be taken continuously over long periods by at-risk patients in order to convey benefit, and document the toxicity of 
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